2017
121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.Peer-Reviewed Original Research
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiology
2015
Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS)
Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia 2015, 15: s44-s45. DOI: 10.1016/j.clml.2015.07.094.Peer-Reviewed Original Research
2012
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.Peer-Reviewed Original ResearchConceptsCost of careMyelodysplastic syndromeMDS patientsMedicare expendituresComparative cost-effectiveness studyCohort of patientsTwo-year survivalNon-cancer controlsCost-effectiveness studiesElderly patientsPrevalent cancerEconomic burdenPatientsMajor subtypesSurvivalCareSyndromeUnited StatesHMAsSurvival probabilityEarly periodCohortAgentsCancerSubtypes